← Comparing 2 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
eIF2α Phosphorylation Imbalance Disrupts Mitochondrial Prote (EIF2S1,eIF2α,PERK,GCN2,ATF4,TOMM20,TIMM23,NDUFS1,NDUFS3,COX4I1,COX5A,mitochondrial protein import) — 0.00 TBK1 Loss Triggers Astrocyte-to-Neuron Senescence Propagatio (TBK1 → NF-κB / IRF3 / p62-autophagy / SASP effectors) — 0.00 TBK1 Loss Triggers eIF2α-Mediated Translational Repression T (TBK1, EIF2S1) — 0.00 GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl (GRIN2B) — 0.96 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.96 Closed-loop optogenetic targeting PV interneurons to restore (PVALB) — 0.95 Plasma NfL Elevation Secondary to BBB-Associated Transport D (NEFL) — 0.94 Closed-loop transcranial focused ultrasound to restore hippo (CCK) — 0.91 Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming (NLRP3, CASP1, IL1B, PYCARD) — 0.91 Gamma entrainment therapy to restore hippocampal-cortical sy (SST) — 0.90 Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Colla (SLC16A1, SLC16A7, LDHA, PDHA1) — 0.89 SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senesc (SIRT1) — 0.89 TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegener (TREM2) — 0.89 Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Pa (APP/PSEN1 (Aβ production), CHAT (cholinergic synthesis)) — 0.89 Optimized Temporal Window for Metabolic Boosting Therapy Det (IFNG) — 0.89 TREM2-APOE Axis Dissociation for Selective DAM Activation (TREM2-APOE axis) — 0.89 p38α Inhibitor and PRMT1 Activator Combination to Restore Ph (MAPK14/PRMT1) — 0.88 APOE-Dependent Autophagy Restoration (MTOR) — 0.88 Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 (BDNF) — 0.87 ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro (ACSL4) — 0.87 Complement Cascade Inhibition Synaptic Protection (%s) — 0.87 eIF2α Phosphorylation Imbalance Creates Integrated Stress Re (EIF2S1,eIF2α,PERK,GCN2,ATF4,ATF5,CHOP,DDIT3,integrated stress response,protein synthesis) — 0.87 Optogenetic restoration of hippocampal gamma oscillations vi (PVALB) — 0.87 Gamma Oscillation Entrainment Enhances lncRNA-9969-Mediated (PVALB, CREB1, lncRNA-9969, neuronal autophagy pathway) — 0.87 Glymphatic-Mediated Tau Clearance Dysfunction (MAPT) — 0.86 Closed-loop focused ultrasound targeting EC-II PV interneuro (PVALB) — 0.86 TREM2 R47H Variant-Driven Metabolic Dysfunction as the Prima (NAMPT) — 0.86 TREM2-Mediated Microglial Dysfunction Disrupts Perivascular (TREM2) — 0.86 Circadian Glymphatic Entrainment via Targeted Orexin Recepto (HCRTR1/HCRTR2) — 0.86 RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA P (RBM45,GSK3B,TDP-43,TARDBP,hnRNP A1,HNRNPA1,phase separation,Liquid droplet) — 0.86
Add
|
× CSF Neurofilament Light C × Plasma p-tau217-Triggered
CSF neurofilament light chain (NfL), lncRNA-0021, astrocyte-derived extracellular vesicles · molecular neurobiology · -
Composite 0.458
Price $0.48
Evidence For 0
Evidence Against 0
## Mechanistic Overview
CSF Neurofilament Light Chain-Guided Astrocyte-Derived Extracellular Vesicle Delivery of lncRNA-0021 in AD starts from the claim that modulating CSF neurofilament light chain (NfL), lncRNA-0021, astrocyte-derived extracellular vesicles within the disease context of molecular neurobiology can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview CSF Neurofilament Light Chain-Guided Astrocyte-Derived Extracellular Vesicle Delivery of
CSF p-tau217 (biomarker), lncRNA-0021, hUC-MSC exosomes · molecular neurobiology · -
Composite 0.323
Price $0.39
Evidence For 0
Evidence Against 0
## Mechanistic Overview
Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window in AD starts from the claim that modulating CSF p-tau217 (biomarker), lncRNA-0021, hUC-MSC exosomes within the disease context of molecular neurobiology can redirect a disease-relevant process. The original description reads: "**Molecular Mechanism and Rationale** The therapeutic hypothesis centers on the precise temporal coordination between plasma phosphorylated tau-217 (p-tau217) biomarke
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
lncRNA-0021 Biomarker Neuroinflammation molecular neurobiology
Convergent signals
lncRNA-0021 recurs across 2 selected hypotheses with aligned directionality in biomarker, neuroinflammation.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary 10/11
dimensions won
CSF Neurofilament Light Chain-Guided Ast
1/11
dimensions won
Plasma p-tau217-Triggered Exosome Dosing
Radar Chart — 10 Dimensions
Score Breakdown
Dimension CSF Neurofilament Light Chain- Plasma p-tau217-Triggered Exos Mechanistic 0.670 0.300 Evidence 0.360 0.150 Novelty 0.500 0.800 Feasibility 0.330 0.120 Impact 0.550 0.250 Druggability 0.500 0.100 Safety 0.500 0.200 Competition 0.450 0.400 Data 0.350 0.100 Reproducible 0.580 0.050 KG Connect 0.633 0.538
Evidence CSF Neurofilament Light Chain-Guided Astrocyte-Derived Extra No evidence citations yet
Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-00 No evidence citations yet
Price History Overlay